According to poor clinical information obtained from the immunohistochemistry (IHC), the interest in EGFR gene status increased after Moroni et al [10] proposed that in CRC the response to anti EGFR treatment with cetuximab is related to EGFR gene copy number (GCN) and Lynch et al [11] showed that, in advanced NSCLC, in-frame deletion or missense mutations in the EGFR TK domain can predict the response to therapy with gefinitib. Here, EGFR is linked to colorectal carcinoma.